ASH 2023: MRD Highlights in BioPharma Drug Development

Read More

Browse our 650+ Publications​

Latest Publications

Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer

Tsai Y, et al.
Frontiers in Immunology
November 2023
Authors and Affiliates
Ya-Yu Tsai 1, Chenxu Qu 2, Joseph D Bonner 3, Rebeca Sanz-Pamplona 4 5 6 7, Sidney S Lindsey 3, Marilena Melas 8, Kevin J McDonnell 3, Gregory E Idos 3, Christopher P Walker 3, Kevin K Tsang 3, Diane M Da Silva 2, Ferran Moratalla-Navarro 4 5 6 9, Asaf Maoz 10, Hedy S Rennert 11, W Martin Kast 2, Joel K Greenson 12, Victor Moreno 4 5 6 9, Gad Rennert 11, Stephen B Gruber 3, Stephanie L Schmit 1 13; 1Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States. 2Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States. 3Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, United States. 4Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain. 5ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 6Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. 7Hospital Universitario Lozano Blesa, Aragon Health Research Institute (IISA), ARAID Foundation, Aragon Government, Zaragoza, Spain. 8Molecular Diagnostics, New York Genome Center, New York, NY, United States. 9Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain. 10Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. 11B. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel. 12Department of Pathology, University of Michigan, Ann Arbor, MI, United States. 13Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Cleveland, OH, United States.

Sex- and age-specific aspects of human peripheral T-cell dynamics

Mika J, et al.
Frontiers in Immunology
November 2023
Authors and Affiliates
Justyna Mika 1, Kengo Yoshida 2, Yoichiro Kusunoki 2, Serge M Candéias 3, Joanna Polanska 1; 1 Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland. 2 Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan. 3 Université Grenoble Alpes, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), Interdisciplinary Research Institute of Grenoble (IRIG), Laboratory of Chemistry and Biology of Metals (LCBM), Grenoble, France.

Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types

Gurung HR, et al.
Nature Biotechnology
November 2023
Authors and Affiliates
Hem R Gurung 1, Amy J Heidersbach 1, Martine Darwish 1, Pamela Pui Fung Chan 1, Jenny Li 1, Maureen Beresini 1, Oliver A Zill 1, Andrew Wallace 1, Ann-Jay Tong 1, Dan Hascall 1, Eric Torres 1, Andy Chang 1, Kenny 'Hei-Wai' Lou 1, Yassan Abdolazimi 1, Christian Hammer 1, Ana Xavier-Magalhães 1, Ana Marcu 1, Samir Vaidya 1, Daniel D Le 1, Ilseyar Akhmetzyanova 1, Soyoung A Oh 1, Amanda J Moore 2, Uzodinma N Uche 2, Melanie B Laur 2, Richard J Notturno 2, Peter J R Ebert 2, Craig Blanchette 3, Benjamin Haley 4, Christopher M Rose 5; 1 Genentech, South San Francisco, CA, USA. 2 Adaptive Biotechnologies, Seattle, WA, USA. 3 Genentech, South San Francisco, CA, USA. cdblanchette@gmail.com. 4 Genentech, South San Francisco, CA, USA. ben.haley@gmail.com. 5 Genentech, South San Francisco, CA, USA. rose.christopher@gene.com.

Renal tubular epithelial cells are constitutive non-cognate stimulators of resident T cells

Sadasivam M, et al.
Cell Reports
November 2023
Authors and Affiliates
Mohanraj Sadasivam 1, Chunfa Jie 2, Abdel Rahim A Hamad 3; 1 Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 664G, Baltimore, MD 21205, USA. 2 Department of Biochemistry and Nutrition, Des Moines University, 3200 Grand Avenue, Ryan Hall 230, Des Moines, IA 50266, USA. 3 Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 664G, Baltimore, MD 21205, USA; Department of Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 664G, Baltimore, MD 21205, USA. Electronic address: ahamad@jhmi.edu.

Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring

Colbert LE, et al.
Cancer Cell
November 2023
Authors and Affiliates
Lauren E Colbert 1, Molly B El Alam 2, Rui Wang 2, Tatiana Karpinets 3, David Lo 2, Erica J Lynn 2, Timothy A Harris 2, Jacob H Elnaggar 4, Kyoko Yoshida-Court 2, Katarina Tomasic 2, Julianna K Bronk 2, Julie Sammouri 2, Ananta V Yanamandra 5, Adilene V Olvera 6, Lily G Carlin 6, Travis Sims 7, Andrea Y Delgado Medrano 2, Tatiana Cisneros Napravnik 2, Madison O'Hara 8, Daniel Lin 2, Chike O Abana 2, Hannah X Li 2, Patricia J Eifel 2, Anuja Jhingran 2, Melissa Joyner 2, Lilie Lin 2, Lois M Ramondetta 7, Andrew M Futreal 3, Kathleen M Schmeler 7, Geena Mathew 2, Stephanie Dorta-Estremera 9, Jianhua Zhang 3, Xiaogang Wu 3, Nadim J Ajami 10, Matthew Wong 10, Cullen Taniguchi 2, Joseph F Petrosino 11, K Jagannadha Sastry 8, Pablo C Okhuysen 6, Sara A Martinez 12, Lin Tan 12, Iqbal Mahmud 12, Philip L Lorenzi 12, Jennifer A Wargo 13, Ann H Klopp 2; 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: lcolbert@mdanderson.org. 2Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; LSU School of Medicine, Louisiana State University, Baton Rouge, LA 70803, USA. 5Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 6Departments of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 7Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 8Department of Thoracic Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 9Department of Microbiology and Medical Zoology, University of Puerto Rico, San Juan, PR 00921, USA. 10Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 11Department of Molecular Virology and Microbiology, The Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, TX 77030, USA. 12Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 13Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; LSU School of Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

A H3K27M-targeted vaccine in adults with diffuse midline glioma

Grassl N, et al.
Nature Medicine
November 2023
Authors and Affiliates
Niklas Grassl 1,2,3, Isabel Poschke 1,4, Katharina Lindner 1,4, Lukas Bunse 1,2,3, Iris Mildenberger 1,2,3, Tamara Boschert 1,4,5, Kristine Jähne 1,2,3, Edward W Green 1,2,3, Ingrid Hülsmeyer 1,4, Simone Jünger 1,4, Tobias Kessler 6,7, Abigail K Suwala 8,9, Philipp Eisele 2, Michael O Breckwoldt 1,3,10, Peter Vajkoczy 11, Oliver M Grauer 12, Ulrich Herrlinger 13, Joerg-Christian Tonn 14, Monika Denk 15, Felix Sahm 8,9, Martin Bendszus 10, Andreas von Deimling 8,9, Frank Winkler 6,7, Wolfgang Wick 6,7, Michael Platten 16,17,18,19,20, Katharina Sahm 21,22,23; 1 DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. 3 DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany. 4 Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 5 Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany. 6 Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany. 7 National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. 8 Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany. 9 DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 10 Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany. 11 Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany. 12 Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. 13 Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany. 14 Department of Neurosurgery, University of Munich LMU, Munich, Germany. 15 Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 16 DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 17 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. m.platten@dkfz-heidelberg.de. 18 DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany. m.platten@dkfz-heidelberg.de. 19 Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 20 Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany. m.platten@dkfz-heidelberg.de. 21 DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.sahm@dkfz-heidelberg.de. 22 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. k.sahm@dkfz-heidelberg.de. 23 DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Hall MS, et al.
Journal for ImmunoTherapy of Cancer
November 2023
Authors and Affiliates
MacLean S Hall 1,2, Jamie K Teer 3, Xiaoqing Yu 3, Holly Branthoover 1, Sebastian Snedal 1, Madeline Rodriguez-Valentin 1, Luz Nagle 1, Ellen Scott 1, Ben Schachner 1, Patrick Innamarato 1, Amy M Hall 1, Jamie Blauvelt 1, Carolyn J Rich 4, Allison D Richards 4, Jake Ceccarelli 5, T J Langer 5, Sean J Yoder 6, Matthew S Beatty 1, Cheryl A Cox 7, Jane L Messina 8, Daniel Abate-Daga 1, James J Mule 1, John E Mullinax 1,9, Amod A Sarnaik 1,4, Shari Pilon-Thomas 10; 1 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 2 Cancer Biology PhD Program, University of South Florida, Tampa, Florida, USA. 3 Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 4 Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 5 Turnstone Biologics, Inc, San Diego, California, USA. 6 Molecular Genomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 7 Cell Therapies Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 8 Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 9 Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 10 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA shari.pilon-thomas@moffitt.org.

Recruitment of naïve CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity

Laing KJ, et al.
Journal of Clinical Investigation
November 2023
Authors and Affiliates
Kerry J Laing 1, Emily S Ford 1, Michael J Johnson 2, Myron J Levin 3, David M Koelle 1, Adriana Weinberg 2; 1 Department of Medicine, University of Washington, Seattle, United States of America. 2 Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, United States of America. 3 Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, United States of America.

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma

Secrier M, et al.
Cancer Research Communication
November 2023
Authors and Affiliates
Maria Secrier 1,2, Lara McGrath 3, Felicia Ng 4, Sakshi Gulati 1, Amelia Raymond 3, Barrett R B Nuttall 3, Julie Berthe 1, Emma V Jones 1, Ben S Sidders 4, Jérôme Galon 5,6,7, J Carl Barrett 3, Helen K Angell 1; 1 Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 2 UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, United Kingdom. 3 Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts. 4 Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 5 INSERM, Laboratory of Integrative Cancer Immunology, Paris, France. 6 Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Paris, France. 7 Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Niemann C, et al.
Lancet Oncology
November 2023
Authors and Affiliates
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P Kater